The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 24, 2002

Filed:

Mar. 04, 1999
Applicant:
Inventors:

Lennart Mucke, Foster City, CA (US);

Tony Wyss-Coray, Berkeley, CA (US);

Eliezer Masliah, Chula Vista, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01K 6/700 ; A01K 6/7027 ; A01K 6/7033 ; G01N 3/300 ;
U.S. Cl.
CPC ...
A01K 6/700 ; A01K 6/7027 ; A01K 6/7033 ; G01N 3/300 ;
Abstract

The present invention features non-human transgenic animal models for Alzheimer's disease (AD) and CAA, wherein the transgenic animal is characterized by 1) expression of bioactive transforming growth factor-&bgr;1 (TGF-&bgr;1) or 2) both expression of bioactive TGF-&bgr;1 and expression of a human amyloid &bgr; precursor protein (APP) gene product. The transgenic animals may be either homozygous or heterozygous for these alterations. Bigenic animals are further characterized by development of AD-associated and/or CAA-associated pathology within about two to three months of age, and at about twelve months of age are characterized by a reduced number of neuritic plaques relative to singly transgenic animals. The invention also features methods of screening for biologically active agents that facilitate reduction of &bgr;-amyloid deposits in vivo and methods for facilitating reduction of formation of neuritic plaques in a subject susceptible to AD.


Find Patent Forward Citations

Loading…